Myelofibrosis
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (KRT-232-115)
- Details
ClinicalTrials.gov ID:
NCT06479135
Diagnosis Type:
NA
USOR Number:
- Address
,
P: